98%
921
2 minutes
20
Sloman and Rabb found support for the existence of the community of knowledge (CK) effect, which occurs when individuals are more likely to report understanding and being able to explain even fake scientific information when told that an expert understands the information. To date, no studies have been conducted that attempted to replicate original findings, let alone test the presence of the CK effect in realistic, legal scenarios. Therefore, Study One replicated original CK effect studies in a jury-eligible M-Turk sample ( = 291) using both Sloman and Rabb's experimental stimuli as well as new stimuli. Study Two then tested the presence of the CK effect using scientific testimony in a mock court hearing from a forensic evaluator ( = 396). Not only did the CK effect improve laypeople's perceptions of the scientific information in court, but it also improved their perceptions of the expert witness's credibility, increased the weight assigned to the scientific information, and increased the weight assigned to the expert testimony. This effect was mediated by participants' perceived similarity to the expert, supporting the theory behind the CK effect. These studies have important implications for the use of scientific information in court, which are discussed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12383182 | PMC |
http://dx.doi.org/10.3390/bs15081071 | DOI Listing |
Graefes Arch Clin Exp Ophthalmol
September 2025
Department of Physics of Condensed Matter, Optics Area. Vision Research Group (CIVIUS), University of Seville, Avenida de la Reina Mercedes s/n (41012), Seville, Spain.
Purpose: To analyze the relationship between various visual function parameters (refractive status, visual acuity and contrast sensitivity) and macular pigment optical density (MPOD) values, as well as dietary intake of lutein and zeaxanthin in a pediatric population.
Methods: Thirty-six healthy White pediatric patients participated in this cross-sectional study conducted at the Optometry Clinic (Faculty of Pharmacy, Seville, Spain). MPOD values were measured using the MPSII (Macular Pigment Screener II).
Pediatr Ann
September 2025
NorthShore University Health System, Evanston, and Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
BJUI Compass
September 2025
Department of Urology and Renal Transplantation, Policlinico Riuniti di Foggia University of Foggia Foggia Italy.
Objective: To investigate the incidence, risk factors and clinical consequences of acute kidney injury (AKI) following mini-percutaneous nephrolithotomy (mini-PCNL), with particular focus on its association with postoperative infectious complications.
Materials And Methods: A retrospective analysis was conducted on 496 adult patients who underwent mini-PCNL (22 Ch) between February 2020 and April 2025. AKI was defined according to KDIGO criteria as either a ≥ 1.
Osteoporos Int
September 2025
Department of Rheumatology, Univ. Lille, CHU Lille, MABlab ULR 4490, 59000, Lille, France.
Medications like liraglutide 3.0 mg daily (Saxenda®; Novo Nordisk) and semaglutide 2.4 mg weekly (Wegovy®; Novo Nordisk), which are glucagon-like peptide-1 receptor agonists (GLP-1Ra), have been sanctioned for prolonged weight management in people living with obesity (PwO).
View Article and Find Full Text PDFHemasphere
September 2025
Hématologie et Hémostase Clinique, CHU de Brest Brest France.
Accelerated-phase (AP) or blast-phase (BP) myeloproliferative neoplasms (MPNs) are associated with dismal prognosis, with non-curative therapies such as hypomethylating agents (HMAs) considered in patients not eligible for intensive therapy, while some studies advocate for combination therapy with either ruxolitinib (RUXO) or venetoclax (VEN). To assess the relationship between treatment modalities and outcome, herein, we report a multicentric cohort of 149 patients (median age, 75 years) with AP/BP MPN not eligible for intensive therapy and/or allogeneic hematopoietic cell transplantation who received azacitidine (AZA) alone ( = 60) or in combination ( = 89; VEN [ = 51], RUXO [ = 27], or both [ = 9], isocitrate dehydrogenase inhibitors [ = 2]) between January 2019 and October 2023. With a median follow-up of 15 months, the median overall survival of the full cohort was 8.
View Article and Find Full Text PDF